vs
Side-by-side financial comparison of Adaptive Biotechnologies Corp (ADPT) and SILICOM LTD. (SILC). Click either name above to swap in a different company.
Adaptive Biotechnologies Corp is the larger business by last-quarter revenue ($71.7M vs $61.9M, roughly 1.2× SILICOM LTD.). SILICOM LTD. runs the higher net margin — -18.5% vs -18.9%, a 0.4% gap on every dollar of revenue. On growth, Adaptive Biotechnologies Corp posted the faster year-over-year revenue change (51.0% vs 6.6%). Adaptive Biotechnologies Corp produced more free cash flow last quarter ($1.4M vs $-3.3M).
ExpreS2ion Biotechnologies is a Danish biotechnology company specialised in the development of new vaccines and immunotherapy products based in Hørsholm, Denmark and listed on the Nasdaq First North Growth Market Sweden.
Silicom Ltd. is a publicly traded company, headquartered in Israel, that specializes in the design, manufacture and marketing of connectivity solutions for a range of servers and server-based systems. Its shares are listed on the NASDAQ Global Market and on the Tel Aviv Stock Exchange. Silicom is a member of the RAD Group family of companies.
ADPT vs SILC — Head-to-Head
Income Statement — Q4 FY2025 vs Q4 FY2025
| Metric | | |
|---|---|---|
| Revenue | $71.7M | $61.9M |
| Net Profit | $-13.6M | $-11.5M |
| Gross Margin | 74.6% | 30.6% |
| Operating Margin | -17.8% | -19.8% |
| Net Margin | -18.9% | -18.5% |
| Revenue YoY | 51.0% | 6.6% |
| Net Profit YoY | 59.7% | 16.3% |
| EPS (diluted) | $-0.08 | $-2.01 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q4 25 | $71.7M | $61.9M | ||
| Q3 25 | $94.0M | — | ||
| Q2 25 | $58.9M | — | ||
| Q1 25 | $52.4M | — | ||
| Q4 24 | $47.5M | $58.1M | ||
| Q3 24 | $46.4M | — | ||
| Q2 24 | $43.2M | — | ||
| Q1 24 | $41.9M | — |
| Q4 25 | $-13.6M | $-11.5M | ||
| Q3 25 | $9.5M | — | ||
| Q2 25 | $-25.6M | — | ||
| Q1 25 | $-29.9M | — | ||
| Q4 24 | $-33.7M | $-13.7M | ||
| Q3 24 | $-32.1M | — | ||
| Q2 24 | $-46.2M | — | ||
| Q1 24 | $-47.5M | — |
| Q4 25 | 74.6% | 30.6% | ||
| Q3 25 | 80.7% | — | ||
| Q2 25 | 69.4% | — | ||
| Q1 25 | 67.6% | — | ||
| Q4 24 | 62.0% | 28.6% | ||
| Q3 24 | 64.1% | — | ||
| Q2 24 | 55.3% | — | ||
| Q1 24 | 56.9% | — |
| Q4 25 | -17.8% | -19.8% | ||
| Q3 25 | 10.9% | — | ||
| Q2 25 | -42.5% | — | ||
| Q1 25 | -56.4% | — | ||
| Q4 24 | -71.3% | -22.8% | ||
| Q3 24 | -70.3% | — | ||
| Q2 24 | -109.6% | — | ||
| Q1 24 | -116.5% | — |
| Q4 25 | -18.9% | -18.5% | ||
| Q3 25 | 10.2% | — | ||
| Q2 25 | -43.5% | — | ||
| Q1 25 | -56.9% | — | ||
| Q4 24 | -71.0% | -23.6% | ||
| Q3 24 | -69.1% | — | ||
| Q2 24 | -107.0% | — | ||
| Q1 24 | -113.5% | — |
| Q4 25 | $-0.08 | $-2.01 | ||
| Q3 25 | $0.06 | — | ||
| Q2 25 | $-0.17 | — | ||
| Q1 25 | $-0.20 | — | ||
| Q4 24 | $-0.22 | $-2.28 | ||
| Q3 24 | $-0.22 | — | ||
| Q2 24 | $-0.31 | — | ||
| Q1 24 | $-0.33 | — |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $70.5M | $42.1M |
| Total DebtLower is stronger | — | — |
| Stockholders' EquityBook value | $218.8M | $117.5M |
| Total Assets | $512.7M | $152.2M |
| Debt / EquityLower = less leverage | — | — |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $70.5M | $42.1M | ||
| Q3 25 | $55.0M | — | ||
| Q2 25 | $43.2M | — | ||
| Q1 25 | $50.6M | — | ||
| Q4 24 | $47.9M | $72.1M | ||
| Q3 24 | $38.1M | — | ||
| Q2 24 | $59.8M | — | ||
| Q1 24 | $71.2M | — |
| Q4 25 | $218.8M | $117.5M | ||
| Q3 25 | $204.4M | — | ||
| Q2 25 | $179.7M | — | ||
| Q1 25 | $190.4M | — | ||
| Q4 24 | $202.7M | $127.8M | ||
| Q3 24 | $223.8M | — | ||
| Q2 24 | $241.6M | — | ||
| Q1 24 | $274.9M | — |
| Q4 25 | $512.7M | $152.2M | ||
| Q3 25 | $490.6M | — | ||
| Q2 25 | $496.6M | — | ||
| Q1 25 | $510.9M | — | ||
| Q4 24 | $539.4M | $150.4M | ||
| Q3 24 | $558.5M | — | ||
| Q2 24 | $584.9M | — | ||
| Q1 24 | $620.3M | — |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $2.1M | $-2.2M |
| Free Cash FlowOCF − Capex | $1.4M | $-3.3M |
| FCF MarginFCF / Revenue | 2.0% | -5.4% |
| Capex IntensityCapex / Revenue | 0.9% | 1.9% |
| Cash ConversionOCF / Net Profit | — | — |
| TTM Free Cash FlowTrailing 4 quarters | $-48.9M | — |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $2.1M | $-2.2M | ||
| Q3 25 | $-7.1M | — | ||
| Q2 25 | $-12.4M | — | ||
| Q1 25 | $-28.5M | — | ||
| Q4 24 | $-12.5M | $18.3M | ||
| Q3 24 | $-27.1M | — | ||
| Q2 24 | $-17.3M | — | ||
| Q1 24 | $-38.4M | — |
| Q4 25 | $1.4M | $-3.3M | ||
| Q3 25 | $-7.5M | — | ||
| Q2 25 | $-13.1M | — | ||
| Q1 25 | $-29.7M | — | ||
| Q4 24 | $-12.6M | $17.4M | ||
| Q3 24 | $-27.4M | — | ||
| Q2 24 | $-19.0M | — | ||
| Q1 24 | $-39.9M | — |
| Q4 25 | 2.0% | -5.4% | ||
| Q3 25 | -8.0% | — | ||
| Q2 25 | -22.2% | — | ||
| Q1 25 | -56.7% | — | ||
| Q4 24 | -26.5% | 29.9% | ||
| Q3 24 | -59.0% | — | ||
| Q2 24 | -44.1% | — | ||
| Q1 24 | -95.2% | — |
| Q4 25 | 0.9% | 1.9% | ||
| Q3 25 | 0.4% | — | ||
| Q2 25 | 1.1% | — | ||
| Q1 25 | 2.4% | — | ||
| Q4 24 | 0.2% | 1.6% | ||
| Q3 24 | 0.7% | — | ||
| Q2 24 | 4.0% | — | ||
| Q1 24 | 3.6% | — |
| Q4 25 | — | — | ||
| Q3 25 | -0.75× | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | — | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — | ||
| Q1 24 | — | — |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
Revenue Breakdown by Segment
ADPT
| Mrd Business Segment | $61.9M | 86% |
| Immune Medicine Business | $9.8M | 14% |
| Immune Medicine Service Revenue | $100.0K | 0% |
SILC
Segment breakdown not available.
